Ask about this productRelated genes to: IGSF8 antibody
- Gene:
- IGSF8 NIH gene
- Name:
- immunoglobulin superfamily member 8
- Previous symbol:
- -
- Synonyms:
- CD81P3, EWI2, PGRL, CD316
- Chromosome:
- 1q23.2
- Locus Type:
- gene with protein product
- Date approved:
- 2002-01-08
- Date modifiied:
- 2016-10-05
Related products to: IGSF8 antibody
Related articles to: IGSF8 antibody
- Immunotherapy has reshaped the oncology landscape by enabling the immune system to recognize and eliminate malignant cells. Although immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death-1 (PD-1), and programmed death-ligand 1 (PD-L1) have achieved durable responses in several cancers, their therapeutic benefit remains limited to a subset of patients, largely due to immune evasion, tumor heterogeneity, and immunosuppressive features of the tumor microenvironment (TME). This review comprehensively examines the expanding landscape of next-generation immune checkpoints, encompassing both co-inhibitory (lymphocyte activation gene-3 [LAG-3], T cell immunoglobulin and mucin-domain containing-3 [TIM-3], TIGIT, VISTA, and IGSF8) and co-stimulatory (ICOS, OX40, GITR, 4-1BB, CD40, and CD27) pathways that collectively regulate the balance between immune activation and tolerance. We discuss their molecular mechanisms, translational rationale, and emerging clinical evidence, highlighting their potential to reinvigorate antitumor immunity, particularly in ICI-refractory settings. Beyond checkpoint modulation, we explore complementary strategies aimed at remodeling the TME and enhancing immune responsiveness, including targeting immunometabolic pathways (IDO1 and CD73), innate immune sensing (toll-like receptors [TLRs]), cytokine signaling (IL-2), micronutrient immunoregulators (vitamin D), and the gut microbiota. The integration of these approaches into rational combination regimens, guided by predictive features such as T cell infiltration, tumor mutational burden (TMB), and microbiome composition, holds promise for extending the clinical impact of immunotherapy across malignancies. We further advocate for a precision immuno-oncology framework that leverages multiomic profiling, systems biology, and artificial intelligence (AI) to optimize therapeutic selection and mitigate immune-related toxicities. Emerging advances in nanomedicine, synthetic biology, and chronotherapy offer additional opportunities to enhance therapeutic specificity and durability, collectively charting a path from mechanistic insight to clinical translation toward realizing the full curative potential of cancer immunotherapy. Trial Registration: ClinicalTrials.gov identifier: LAG-3 (NCT03470922, NCT04082364, NCT05064059, NCT05352672, NCT02614833, NCT03625323, NCT01968109), TIM-3 (NCT03307785, NCT03680508, NCT02608268, NCT02817633), TIGIT (NCT03563716), VISTA (NCT02671955, NCT02812875), IGSF8 (NCT05669430), CD73 (NCT02503774), B7-H3 (NCT02475213, NCT01391143, NCT02628535, NCT03406949, NCT00089245, NCT01099644, NCT01502917), OX40 (NCT01862900, NCT02315066, NCT02410512, NCT02221960, NCT02528357, NCT02923349, NCT02705482), CD27 (NCT02335918, NCT02924038, NCT02302339, NCT02386111, NCT02543645), 4-1BB (NCT01307267, NCT02444793, NCT01471210, NCT02253992, NCT02554812), CD40 (NCT02588443, NCT03329950), ICOS (NCT02904226, NCT02723955, NCT03251924), GITR (NCT02583165, NCT02132754, NCT02697591, NCT03126110, NCT02740270, NCT02598960, NCT01239134, NCT02628574), IDO1 (NCT02752074, NCT02658890, NCT02077881, NCT01560923, NCT02073123, NCT02327078, NCT02178722), TLRs (NCT02556463, NCT02042781), and IL-2-based therapies (NCT02869295, NCT02983045). - Source: PubMed
Bautista JhommaraEcheverría Carolina EMaldonado-Noboa IvánAdatty-Molina JosethSuárez Urresta SaloméCoral-Riofrio Emily CAraujo-Abad SaloméKyriakidis Nikolaos CLópez-Cortés Andrés - R3HDM4, or R3H domain containing 4, is a gene with uncertain functions but is frequently investigated for its potential cellular roles and associations with various diseases. Kidney renal clear cell carcinoma (KIRC ), a prevalent and aggressive form of kidney cancer, currently lacks effective treatment options. This study aimed to clarify the involvement of R3HDM4 in KIRC pathogenesis. - Source: PubMed
Publication date: 2025/11/19
Sun KaiLi RongXu TingWen SongXu De-ChangWang Ke-Run - Gastric cancer (GC), originating from gastric mucosa epithelial cells, is a global health issue, ranking as the fifth most common cancer and fourth in cancer-related deaths. Stomach adenocarcinoma (STAD) accounts for 95% of GC cases. Emerging evidence suggests a link between manganese (Mn) metabolism and GC, but the role of Mn metabolism-related genes (MMRGs) in STAD is unclear. This study aims to bridge this gap of Mn metabolism through the development of a robust prognostic signature derived from The Cancer Genome Atlas (TCGA) data. - Source: PubMed
Publication date: 2025/10/22
Li DouWei DanLi LianyongZhong ChangqingBao XinweiZhang WenjuanSui Xinke - The aim of this study was to search for human genes potentially involved in the pathogenesis of hepatitis C by multi-network bioinformatics linkage analysis of proteins involved in the stages of hepatitis C virus (HСV) attachment and entry. - Source: PubMed
Publication date: 2025/07/21
Anufrieva E VOstankova Y VDavydenko V SSchemelev A NTotolian A A - Immunoglobulin superfamily member 8 (IGSF8) is a membrane protein implicated in crucial biological processes like cell interactions and immune responses. Emerging evidence suggests that IGSF8 plays a significant role in various cancers by influencing tumor progression through regulation of cell proliferation, migration, and apoptosis. Analyzing its expression, mutation status, and clinical correlations across different cancer types through pan-cancer bioinformatics could provide valuable insights into its potential as a biomarker and target for cancer therapies. - Source: PubMed
Publication date: 2025/08/27
Wang JieLu LingxiaoWu RuichengLi DengxiongWang ZhipengYe LuxiaFeng Dechao